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Current risk stratiﬁcation schemas for medulloblastoma,
based on combinations of clinical variables and histo-
type, fail to accurately identify particularly good- and
poor-risk tumors. Attempts have been made to
improve discriminatory power by combining clinical
variables with cytogenetic data. We report here a
pooled analysis of all previous reports of chromosomal
copy number related to survival data in medulloblas-
toma. We collated data from previous reports that expli-
citly quoted survival data and chromosomal copy
number in medulloblastoma. We analyzed the relative
prognostic signiﬁcance of currently used clinical risk
stratiﬁers and the chromosomal aberrations previously
reported to correlate with survival. In the pooled
dataset metastatic disease, incomplete tumor resection
and severe anaplasia were associated with poor
outcome, while young age at presentation was not prog-
nostically signiﬁcant. Of the chromosomal variables
studied, isolated 17p loss and gain of 1q correlated
with poor survival. Gain of 17q without associated
loss of 17p showed a trend to improved outcome.
The most commonly reported alteration, isodicentric
chromosome 17, was not prognostically signiﬁcant.
Sequential multivariate models identiﬁed isolated 17p
loss, isolated 17q gain, and 1q gain as independent prog-
nostic factors. In a historical dataset, we have identiﬁed
isolated 17p loss as a marker of poor outcome and 17q
gain as a novel putative marker of good prognosis.
Biological markers of poor-risk and good-risk tumors
will be critical in stratifying treatment in future trials.
Our ﬁndings should be prospectively validated indepen-
dently in future clinical studies.
Keywords: Medulloblastoma, survival, risk
stratiﬁcation, cytogenetic, isochromosome, i(17q),
monosomy 6, 1q gain, 17p loss, 17q gain.
M
edulloblastomas are the most common malig-
nant brain tumors of childhood. Reﬁnements
in clinical risk stratiﬁcation, combined with
more intensive treatment protocols, have resulted in sur-
vival estimates for patients with standard risk disease in
excess of 80% at 5 years.
1,2 However, current risk stra-
tiﬁcations still rely largely on clinical factors—age, pres-
ence of metastatic disease, and extent of resection—
combined with histological subtype and do not yet accu-
rately discriminate either the children who will be cured
with current treatment or those who will die of disease
despite optimal treatment. Although expression proﬁl-
ing has been shown to be the best predictor of
outcome,
3,4 several less costly histopathological and bio-
logical risk factors have also shown utility,
5–10 and stra-
tiﬁcation schemes relying on combinations of clinical
factors, chromosomal copy number changes, and immu-
nohistochemistry have been suggested.
8,11–13
The chromosomal changes reported to predict survi-
val in medullolastoma include loss of 17p,
7,14,15 gain
of 17q,
8,15 presence of an isodicentric chromosome 17
(idic(17)(p11.2)),
7,16 gain of 1q,
17 and monosomy
6 in association with WNT pathway activation.
18,19
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Advance Access publication February 2, 2011However, medulloblastomas are rare tumors and most
reports of biological variables with putative pronostic
signiﬁcance are based on small series. We sought to
identify the prognostic impact of these chromosomal
changes in a larger dataset. By combining our previously
reported series of 41 medulloblastomas
20 with other
series with explicit survival data related to chromosomal
copy number abnormalities, we generated a combined
dataset representing 227 patients. We report here our
results from correlating alterations in chromosomes
1q, 6, and 17 with survival in the combined dataset.
Materials and Methods
Selection of Datasets
All studies that reported separate data for gain and loss
of individual chromosome arms were included in
the analysis. The datasets included are summarized
in Table 1. Several additional studies (total n ¼ 95
patients) reported data from ﬂuorescence in situ hybrid-
ization (FISH), loss of heterozygosity analyses, or a com-
bination but did not give separate information on gain
and loss for each chromosome arm.
21–25 They were
not included in the analysis.
Data Collection
For each study, data on loss and gain were collected sep-
arately for each chromosome arm. To allow direct com-
parisons between the datasets, copy number changes
along a whole chromosome arm were grouped together.
Reporting of metastatic disease at presentation was vari-
able. Some authors reported Chang stage, and others
reported metastases to be present or absent. Where
Chang staging was presented, all tumors staged at
.M0 were classed as metastatic. It was not always poss-
ible to differentiate death from disease and death from
other causes. To maximize the sample size, only
overall survival data were analyzed. Event-free and
progression-free survival data, although included in
some reports, were not analyzed. Some series reported
data on samples from initial presentation and from
relapsed disease. To increase homogeneity within the
dataset, samples from relapsed tumors were excluded
from the analysis.
Statistical Analysis
All statistical computations were carried out in R.
26
Log-rank tests were used to evaluate differences in survi-
val. Survival curves were estimated using the Kaplan–
Meier method, and the resulting curves were used to esti-
mate 5-year overall survival (OS). Cox’s proportional
hazards model was used to evaluate the contribution
of individual risk variables to outcome. However, only
65/227 samples had a complete dataset for all variables
examined. Therefore, to maximize the number of
samples included in validating the model, we planned
a series of modiﬁed multivariate models (n ¼ 15) that
systematically examined all possible combinations of
input variables with missing data in addition to chromo-
some 17 variables, for which data were complete. For
each combination of input variables, cases with
missing data were excluded and the model was applied
to the modiﬁed dataset. A criterion-based variable selec-
tion procedure was used to select the variables included
in the ﬁnal model for each combination according to the
R package bootStepAIC. Models were internally vali-
dated to assess the stability of individual variables by
performing 1000 bootstrap iterations per model. This
resulted in a series of bootstrapped models of progress-
ively decreasing sample size with combinations of prog-
nostic variables. The input and output variables for each
model are reported.
Results
Six studies (n ¼ 186 samples) reported chromosomal
comparative genomic hybridization (CGH) or array
CGH data,
17,27–31 and a further study (n ¼ 41) reported
FISH data for chromosome 17.
13 Treatment details were
given for 130 patients (57%), of whom 81 (62%) had
surgery and chemoradiotherapy, 39 (30%) had surgery
and radiotherapy, and 5 (4%) had surgery alone. The
median age at surgery was 8.5 years (range 0 to 43).
Radiotherapy was given to 91% of children (,16
years) and 96% of adults for whom data were available.
A greater proportion of children had additional che-
motherapy (78% vs 24%). The full dataset is given in
the Supplemental Data.
The Prognostic Signiﬁcance of Established Clinical Risk
Factors in the Dataset Reﬂected Previous Reports
In total, 52 patients (26%) had metastatic disease. There
was a clear survival disadvantage for these patients. The
predicted 5-year survival rates for those with and
without metastases were 41+7% and 70+4% (p ,
0.001; Fig. 1A). Gross tumor resection was achieved in
77/138 (56%) for whom data were reported and was
associated with an improved outcome (5-y OS 75+
5% versus 50+7%, p , 0.001; Fig. 1B). The estimated
5-year OS for patients with nonmetastatic, completely
resected tumors was 81+5%. Age at diagnosis was
not a prognostic factor in this dataset. The ﬁve-year
OS for those aged under 3 (n ¼ 28/227, 21%) was
68+9% versus 63+4% for those over 3 (p ¼
0.827). The adult (≥16 years) 5-year OS was 65+4%
versus 57+9% for children (p ¼ 0.292).
Histological details were recorded for 184 patients
(81%). The tumors were classiﬁed as classic (n ¼ 108,
59%), desmoplastic/nodular (n ¼ 48, 27%), showing
focal moderate anaplasia (n ¼ 1 4 ,8 % ) ,m o d e r a t ea n a p l a -
sia (n ¼ 5, 3%), or severe anaplasia (n ¼ 9, 5%). Tumors
with severe anaplasia had a worse outcome on univariate
analysis (3-y OS 11+11% vs 72+4%). Other histo-
types had no prognostic impact (Fig. 1C). Correlation of
particular copy number aberrations with histotypes was
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cases with severe anaplasia had a high incidence of 1q
gain (6/9 cases, 67%, chi-square p ¼ 0.007), and
nodular/desmoplastic tumors had a particularly low inci-
dence of idic(17)(p11.2) (6/48 cases, 13%, p ¼ 0.013).
Loss of 17p and Gain of 17q Had Opposite Prognostic
Associations
In total, 81/227 cases (36%) had 17p loss, the majority
(n ¼ 64) in the context of an idic(17)(p11.2).
Idic(17)(p11.2) formation had no prognostic value (5-y
OS 58+7% vs 65+4%, p ¼ 0.444). Isolated loss of
17p without associated 17q gain was identiﬁed less fre-
quently (n ¼ 15) but was associated with a signiﬁcantly
worse outcome (5-y OS 18+14% vs 66+4%, p ¼
0.003). Gain of 17q was seen in 103/227 cases (45%)
and had no impact on survival (5-y OS 66+5% vs
61+5%, p ¼ 0.461). However, over half of the cases
(64/104, 62%) had an idic(17)(p11.2). The remainder,
without associated 17p loss, showed a trend toward
improved survival (5-y OS 78+7% vs 60+4%, p ¼
0.128). Thus, classiﬁcation based on chromosome 17
data alone indicated a survival hierarchy (Fig. 2A),
with estimated 5-year OS rates of 78%+7% for iso-
lated 17q gain, 69+5% with normal chromosome 17,
58+7% with idic(17)(p11.2), and 18+14% with iso-
lated 17p loss. Of note, the cases with 17q gain consisted
approximately equally of trisomy 17 and isolated gain of
17q. Both subsets showed the same trend toward
improved survival, although the smaller sample sizes in
each group resulted in less signiﬁcant differences in
outcome when analyzed individually. Loss and gain of
small regions within chromosome 17 were reported
only rarely. There were no overlapping minimal
regions of loss or gain.
When the chromosome 17 outcome data were strati-
ﬁed according to clinical criteria, the survival advantage
was still apparent. For metastatic disease, two patterns
were seen (Fig. 2B). In general, patients with nonmeta-
static disease had better 5-year OS (72+8% to
75%+9%) than those with metastatic disease (8+
8% to 49+11%), with the following two exceptions.
Gain of 17q without associated 17p loss was associated
with good survival and isolated loss of 17p with poor
survival irrespective of metastatic disease.
Stratiﬁcation by surgical resection revealed a similar
pattern. Isolated 17q gain was associated with good sur-
vival—estimated 5-year OS 81+12% and 78+14%
following complete and incomplete resection, respect-
ively. In contrast, isolated 17p loss was associated with
poor survival—estimated 5-year OS 0% and 17
+14% following complete and incomplete resection.
Tumor resection had no demonstrable effect on survival
for cases with an idic(17)(p11.2) (5-y OS 63+11% and
56+12%). For cases with a normal chromosome 17,
the completeness of resection had a greater impact (5-y
OS 83+6% and 51+12%, respectively).
An attempt was made to analyze the prognostic sig-





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































McCabe et al.: Genomic risk factors in medulloblastoma
378 NEURO-ONCOLOGY † APRIL 2011separately. The subgroup analysis revealed identical
trends in adults and children, although the reduction in
numbers in each subgroup led to a fall in statistical sig-
niﬁcance. Stratiﬁcation by chromosome 17 data alone
demonstrated best survival in the subgroups with iso-
lated 17q gain (adult n ¼ 3, 5-y OS 100%; child n ¼
36, 5-y OS 76+8%) and the worst for isolated 17p
loss (adult n ¼ 5, 5-y OS 0%; child n ¼ 10, 5-y OS
47+17%). This chromosome 17–based survival hier-
archy was more striking for adults (p ¼ 0.004) than chil-
dren (p ¼ 0.162). Further subgroup analysis stratiﬁed by
metastatic disease status and completeness of resection
was precluded by small or absent numbers in several
subgroups, although where data were present the same
trends were observed.
Copy number data for 1q and chromosome 6 were
available from studies reporting chromosomal or array
CGH (total n ¼ 186).
17,28–31 On univariate analysis of
the pooled dataset, gain of 1q (36/186, 19%) was
associated with worse outcome (5-y OS 49+9% vs
69+4%, p ¼ 0.021; Fig. 3A). Only 2 adults had 1q
gain, precluding meaningful subgroup analysis based
on age. The association between 1q gain and poor
outcome has been reported in only a single series, by
Lo et al.
17 When these data were removed from the
dataset (remaining n ¼ 138), outcome was equal
between those with and without 1q gain (5-y OS 58+
10% and 66+5, respectively, p ¼ 0.53; Fig. 3B).
Monosomy 6 was a rare ﬁnding, seen in only 8/186
cases (4%, 7 children, 1 adult). Although the survival
curve showed superior survival for cases with monos-
omy 6, there was no statistical difference in survival
between the two groups (5-y OS 75+15% and 64+
4%, respectively, p ¼ 0.583; Fig. 3C). Two of the
Fig. 2. The inﬂuence of chromosome 17 alterations on survival. (A) Chromosome 17 alterations were associated with signiﬁcantly different
outcomes. Estimated 5-year survival for isolated 17q gain, isodicentric chromosome 17, and isolated 17p loss were 78%+7%, 58+7%,
and 18+14%, respectively. (B) The prognostic associations of 17p loss and 17q gain were still apparent following stratiﬁcation according to
clinical risk criteria. Metastatic patients with 17q gain had predicted 5-year OS similar to that of nonmetastatic patients. The longest surviving
patient with 17q gain, with an incompletely resected primary tumor and metastatic disease, died at 9.2 years. The cause of death was not
clear. In contrast, isolated 17p loss was associated with poor outcome, irrespective of the presence or absence of metastases.
Fig. 1. Univariate analysis of established clinical risk factors in the combined dataset. The Kaplan–Meier method was used to estimate
survival according to the presence of metastases at diagnosis (A), the extent of primary surgical resection (B), and histological subtype
(C). Survival in the dataset was inferior for the groups with metastatic disease (5-yr OS 41+7% vs 70+4%) and incomplete resection
(5-yr OS 50+7% vs 75+5%). Severe anaplasia correlated with poor survival (3-yr OS 11+11% vs 72+4%).
Martin et al.: Genomic risk factors in medulloblastoma
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2 years of diagnosis. Details of treatment, metastatic
disease, and tumor resection were not available for all
cases, including the patients who died.
We attempted to ﬁt a Cox proportional hazards
model to the data to determine whether the chromoso-
mal alterations studied had additive predictive value
over established clinical risk factors. However, although
all studies reported complete chromosome 17 data,
reporting of other variables was inconsistent between
studies and only a minority of cases (65/227, 29%)
had a complete dataset. The proportional hazards
model based on these few cases contained only the clini-
cal variables of metastatic disease, incomplete resection,
and severe anaplasia.
To maximize the number of cases for which a multi-
variate model could be built, we created a series of modi-
ﬁed datasets(n ¼ 15) designed to systematicallyexamine
all possible combinations of variables in addition to
chromosome 17, as described in the Methods section.
We then ﬁt multivariate models to the modiﬁed datasets
using a bootstrapped criterion-based variable selection
procedure (1000 bootstrap iterations per model).
Details of the combinations of input variables and
those included in the ﬁnal models are shown in
Table 2. Metastatic disease and incomplete resection
remained prognostically signiﬁcant in all models in
which they were included (n ¼ 8); histological subtype
was prognostic in 6/8 models (75%); isolated 17p loss
in 8/15 (53%); 17q gain without idic(17)(p11.2) in 4/
15 (27%); 1q gain in 2/8 (25%) and idic(17)(p11.2)
in 2/15 (13%). Monosomy 6 was not retained as a sig-
niﬁcant variable in any of the ﬁnal models.
Discussion
The historical nature of this dataset is reﬂected in the
relatively low rate of complete surgical resection and
the relatively high number of patients who were not
given combined chemoradiotherapy following surgery.
However, although treatment for medulloblastoma has
changed signiﬁcantly during the 13 years spanning the
studies included in this analysis, for patients with com-
pletely resected, nonmetastatic tumors the 5-year survi-
val of 81+5% was comparable to that reported by
recent large, prospective trials. Notwithstanding recent
improvements in therapy, metastatic disease (Chang
stage M2-3) continues to predict poor survival in pro-
spective series.
1,32,33 The inﬂuence of completeness of
tumor resection on outcome is less clear, and large
trials that report current best practice therapy have
reported conﬂicting results.
32,34
Gain of 17q Has Not Previously Been Identiﬁed
as a Predictor of Good Risk
Here we report associations between 17p loss and poor
outcome and between 17q gain and improved
outcome. Until recently the issue of chromosome 17
alterations in predicting outcome has been confused by
several factors. Most studies have reported small
numbers, with insufﬁcient power to detect survival
effects, and several authors have therefore reported
chromosome 17 alterations to have no impact on survi-
val.
11,17,21–24,35 The variables correlated to survival
have been 17p loss,
14,22,23,35,36 idic(17)(p11.2) for-
mation,
21,24 17q gain or a combination of
these,
8,11,15–17 and the analysis of multiple different
chromosome 17 alterations using a variety of techniques
has further confused the issue. The analysis we report
here from a large, pooled historical dataset indicates
that isolated 17p loss, idic(17)(p11.2) formation, and
isolated 17q gain have markedly different prognostic
value.
Isolated 17p loss has recently been reported to corre-
latewith poor outcome by several independent groups in
addition to this report.
7,8,13 Our identiﬁcation of a trend
toward improved outcome with isolated 17q gain is
novel. One previous study has correlated 17q alterations
with survival.
8 Explicit data were not reported. In that
Fig. 3. The inﬂuence of other chromosomal alterations on survival. In the combined dataset, univariate analysis showed 1q gain to be
associated with inferior survival (A). However, the data were skewed by a single report with a high mortality rate for cases with 1q gain.
When those data were removed (B), there was no survival difference between the two groups. (C) Monosomy 6 was a rare ﬁnding.
Although there was an appearance of improved outcome for these cases, the difference was not statistically signiﬁcant.
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with poor OS. In direct contrast to our data, however,
isolated 17q gain was also correlated with poor
outcome. Reasons for the discrepancy between the
studies are not immediately clear. The analysis we
report and that of Pﬁster and colleagues share common
drawbacks. They are both retrospective and report a
variety of therapeutic protocols. In the Pﬁster study
alone, at least 4 protocols were followed. Both studies
used a combination of CGH (or array CGH) and FISH
to analyze copy number. In the dataset we report here,
all cases of 17q gain without 17p loss were identiﬁed
using metaphase or array CGH, while in the Pﬁster
study, 43/50 samples with 17q gain were identiﬁed
using interphase FISH. In our hands, dual color inter-
phase FISH has given unreliable results in the detection
of single copy gain, due to difﬁculty in reliably dis-
tinguishing closely packed adjacent nuclei in parafﬁn-
embedded tissue (unpublished data). Nonetheless the
Pﬁster dataset was large and its 17q ﬁndings were repli-
cated in atestset (n ¼ 80) and avalidation set (n ¼ 260).
Our dichotomous ﬁndings are interesting and should be
further explored in future prospective studies. Why 17p
loss should associate with poor survival and 17q gain
with improved survival are not clear.
The Speciﬁc Relationship between Monosomy 6
and Outcome Is Not Yet Clear
Severalindependent groups have recentlyreported associ-
ations between monosomy 6, mutations of the catenin
(cadherin-associated protein) beta 1 gene (CTNNB1),
nuclear immunopositivity for CTNNB1, and nonmeta-
static disease.
10,18,19,40 The precise relationships between
these factors are yet to be established. To date there is
insufﬁcient evidence to support the biological equivalence
of nuclear beta-catenin expression, CTNNB1 mutations,
and wingless-integrated (Wnt) pathway activation, and it
is not clear why alterations in the sequence or expression
of CTNNB1 should relate to loss of one copy of chromo-
some 6. To our knowledge, 21 cases have so far been
reported with monosomy 6 in association with either
nuclear CTNNB1 expression, CTNNB1 mutations, or
Wnt pathway activation. Other cases are reported either
with monosomy 6 and no evidence of Wnt pathway acti-
vation (n ¼ 2)
19 or evidence of Wnt/CTNNB1 activation
without monosomy 6 (n ¼ 7).
10,19,40 However, while
there is strong evidence of an association between
nuclear CTNNB1 expression and improved survival,
9,10
thespeciﬁclinksbetweenmonosomy6,Wntpathwayacti-
vation, and survival have yet to be identiﬁed. Our pooled
data did not support a prognostic relationship. However,
monosomy 6 is a very rare ﬁnding in medulloblastoma,
precluding meaningful analysis outside of a very large
series of tumors. Of interest, in keeping with previous lit-
erature, none of the patients with monosomy 6 in our
pooled dataset had metastatic disease.
In conclusion, we have analyzed the prognostic value
of chromosomal alterations in a large, combined dataset
of medulloblastomas. We have shown that isolated 17p
loss had clear negative prognostic value, while isolated
17q gain showed a trend to improved outcome indepen-
dently of clinical criteria. We have shown that
idic(17)(p11.2) did not clearly correlate with outcome.
Table 2. Multivariate models. To minimize the effects of missing data, a series of modiﬁed datasets were generated to systematically
examine combinations of input variables while excluding missing data. Multivariate models were built from these data using a
bootstrapped criterion-based variable selection procedure with the R program “bootStepAIC.” The combinations of variables examined
in each model and the effect on sample size of excluding cases with missing values are shown. Each row corresponds to one model.
Variables selected for inclusion in the ﬁnal model for each combination are highlighted gray. The variables included in ≥25% of ﬁnal
models were (in decreasing order of stability) metastatic disease and incomplete resection, severely anaplastic histology, isolated 17p loss,














201 †† † † ,0.001
186 †† † † † 0.019
184 †† † † ,0.001
173 †† † † † ,0.001
161 †† † † † † ,0.001
143 †† † † † † 0.002
138 †† † † ,0.001
133 †† † † † † † ,0.001
132 †† † † † ,0.001
111 †† † † † ,0.001
105 †† † † † † ,0.001
97 †† † † † † 0.038
92 †† † † † † † 0.025
70 †† † † † † † 0.006
65 †† † † † † † † 0.004
*17q gain and 17p loss not in the context of an idic(17)(p11.2).
**Likelihood ratio test p-value.
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ciently robust to show a convincing association between
1q gain and survival. The ﬁndings from this historical
series should be investigated in future prospective
studies. The identiﬁcation of particularly poor-risk and
good-risk tumors, even if the relative numbers are
small, will be critical in stratifying treatment in future
trials. A signiﬁcantly greater challenge will be to identify
the single-gene correlates of the large-scale chromoso-
mal changes discussed here.
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Supplementary material is available at Neuro-Oncology
online.
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